Core Viewpoint - The strategic investment by Zhong Shanshan in Jinbo Biological is seen as a significant move into the collagen protein sector, indicating confidence in the company's growth potential and the broader medical beauty industry [2][8]. Group 1: Investment Details - Jinbo Biological announced the introduction of strategic investors, raising a total of 3.4 billion yuan, with 2 billion yuan allocated to the issuance of shares to Yangshengtang [2][3]. - Zhong Shanshan, through Yangshengtang and Hangzhou Jiushi, will hold a combined 10.58% stake in Jinbo Biological after the transaction [5][6]. - The investment aims to enhance Jinbo Biological's production capabilities and market reach, leveraging Yangshengtang's resources [10]. Group 2: Company Performance - Jinbo Biological reported a revenue of 1.443 billion yuan in 2024, marking an 84.92% year-on-year increase, with a net profit of 732 million yuan, up 144.27% [15]. - The company boasts a high gross margin of 92.02% and a net profit margin of 50.68%, reflecting strong profitability [15]. - Jinbo Biological is recognized as a leader in the recombinant human collagen field, having achieved significant technological breakthroughs [15]. Group 3: Market Context - The medical beauty sector is becoming increasingly competitive, with Jinbo Biological facing challenges from rivals like Juzhi Biological and Marubi [11]. - Yangshengtang's recent performance has been lackluster, with its main companies, Nongfu Spring and Wantai Biological, showing minimal revenue growth [13][14]. - The investment by Zhong Shanshan may be a strategic move to diversify and seek new growth avenues amid stagnation in his existing businesses [13][16].